Review finds ultra-low-dose CT detects many lung nodules with less radiation
The analysis found lower radiation exposure but less reliable detection of very small or hazy nodules and in people with higher body weight.
High evidenceReviewSome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers reviewed original studies published from 2015 through 2025 that assessed ultra-low-dose CT for detecting lung nodules. They combined results statistically where possible and also examined whether different image-reconstruction methods affected performance.
In the studies included in the pooled analysis, ultra-low-dose CT detected about 92% of nodules on average. The estimate was highly variable across studies. Advanced reconstruction methods showed a higher sensitivity estimate than standard iterative reconstruction, but the difference was not statistically significant. The review reported lower sensitivity for subsolid, ground-glass, and nodules smaller than 6 millimeters, as well as reduced performance in patients with a high body mass index.
What the review examined
The researchers conducted a systematic review and meta-analysis following PRISMA guidelines. They searched PubMed, the Cochrane Library, and Ovid MEDLINE for original research published between 2015 and 2025 on ultra-low-dose CT for pulmonary nodule detection. Forty-two studies involving 15,792 patients were included overall. A statistical meta-analysis of 11 studies assessed pooled sensitivity for detecting nodules, and a separate analysis of 12 studies assessed mean effective radiation dose. The researchers also performed a subgroup analysis of image-reconstruction methods.
Key conclusions
The pooled sensitivity for pulmonary nodule detection was 91.9%, with a 95% confidence interval of 84.6% to 97.1%. Results differed substantially across studies, with statistical heterogeneity of I²=93.0%. The pooled mean effective radiation dose was 0.22 mSv, with a 95% confidence interval of 0.11 to 0.33 mSv; the review described this as comparable to standard chest radiography.
Sensitivity was estimated at 96.7% with advanced reconstruction methods and 87.9% with standard iterative reconstruction, but this difference was not statistically significant (p=0.091). The narrative review indicated that performance was stronger for solid nodules and lower for subsolid, ground-glass, and small nodules, particularly those smaller than 6 mm. Performance was also limited in patients with a high body mass index. The abstract reports sensitivity findings but does not provide a pooled estimate of specificity.
Who this is relevant to
These findings may be most relevant to patient groups, scanners, imaging protocols, and clinical settings similar to those represented in the included studies. They may not apply equally to people with very small, subsolid, or ground-glass nodules or to patients with a high body mass index. Because the review found substantial variation between studies and did not establish performance for every clinical use, its results should not be interpreted as applying uniformly to all patients or as showing that ultra-low-dose CT is equivalent to standard-dose CT in every circumstance.
The significance
The findings suggest that ultra-low-dose CT can detect many solid lung nodules while exposing patients to relatively little radiation in the studies reviewed. This could be relevant to imaging protocols in settings where repeated scans or radiation exposure are concerns. However, the results do not establish that ultra-low-dose CT performs equally well for every nodule type, patient body size, or clinical purpose, and the study did not show that it is interchangeable with standard-dose CT in all situations.
Limitations & evidence assessment
The largest limitation was the very high variation between studies, which makes the pooled sensitivity less certain as a single estimate. Although 42 studies were included, only 11 contributed to the pooled sensitivity analysis and 12 to the radiation-dose analysis. The review also found weaker performance for subsolid, ground-glass, and very small nodules and in patients with a high body mass index. The abstract provides limited information about the individual studies, including how patients were selected, how nodules were confirmed, and whether study quality or risk of bias affected the results. The analysis reported a trend favoring advanced reconstruction methods, but that difference was not statistically significant.
Why this evidence level: Meta-analysis pooling multiple studies sits at the top of common evidence hierarchies.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
In an online randomized experiment involving 3,519 Chilean parents, researchers tested whether adding an “ULTRAPROCESSED” warning to Chile’s existing nutrient labels changed views of potato chips. The added label improved identification of ultraprocessed products and lowered reported purchase intentions and perceived healthfulness, but the effects were smaller when products already had more nutrient warnings. The study measured stated responses, not actual purchases or health outcomes.
A systematic review and network meta-analysis examined nonhormonal prescription medicines for hot flashes and related symptoms among adult women with breast cancer or a history of breast cancer. Across 19 study or substudy records involving 2,224 participants, five medicines showed statistically greater symptom improvement than placebo, but the evidence for comparing safety between medicines was limited.
Researchers compared outcomes among people with relapsed or treatment-resistant multiple myeloma who received teclistamab plus daratumumab or one of two other daratumumab-based combinations. In this adjusted analysis of data from three clinical trials, the teclistamab combination was associated with longer progression-free and overall survival and deeper responses. Because the comparison used data from separate trials, it cannot establish that one regimen caused the better outcomes.
